Hey Aamir, check out July's top stories: The fall of Vinay Prasad, Woebot, and possibly Sarepta?

Find out all the details in these STAT+ stories with 25% off an annual STAT+ subscription.

My Account    STAT+ Check out June's top stories. If you like what you see, join the STAT+ community today – and enjoy 25% off your first year with code LOYAL25. Courtesy FDA 1   Vinay Prasad, a powerful FDA official, departs after controversy over rare disease drug By Lizzy Lawrence, Adam Feuerstein, and Matthew Herper Jose Luis Magana/AP 2   Inside the staff exodus and tanking morale that threaten Makary's FDA By Lizzy Lawrence Chip Somodevilla/Getty Images 3   Trump administration reverses course, lifts pause on NIH grant awards By Angus Chen, Megan Molteni, and Anil Oza 25% off STAT+ Get 25% off your first year of STAT+ with discount code LOYAL25. SUBSCRIBE NOW More Top Stories 4   Why Woebot, a pioneering therapy chatbot, shut down By Mario Aguilar 5   HHS devises legal playbook for future grant terminations, internal memo shows By Anil Oza 6   The crisis over Sarepta's Duchenne therapy is a mess. But the lesson is clear By Matthew Herper 7   Why Sarepta may not survive its current gene therapy crisis By Adam Feuerstein 8   Medicare proposes 'efficiency' pay cuts that would hit highly paid specialists the most By Bob Herman and Tara Bannow 9   Did a drug prevent this man's ALS? By Jason Mast 10   Terminated NIH grants are being reinstated almost entirely in blue states By Anil Oza read more STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us